JPMorgan Raises Eli Lilly Price Target to $1,400 on Mounjaro’s Obesity and Pediatric Momentum
Health Canada has approved Mounjaro for children with type 2 diabetes.
/ 1648 items
#XY↓
Benchmark Upgrades AbCellera to Buy with $11 Target on Major Jazz Pharmaceuticals Partnership
AbCellera gets a boost after Jazz deal brings upfront cash and future growth potential through cancer antibody programs and milestones.
Kyntra Bio Scores First Analyst Coverage: Oppenheimer Initiates Outperform with $35 Target
Kyntra Bio gains analyst support as its cancer drugs advance, with key Phase 2 data expected to drive future growth.
Aligos Therapeutics Shares Soar on Major China Licensing Agreement and Regulatory Milestone for Chronic Hepatitis B Treatment
Aligos Therapeutics announces $25 million upfront payment and Breakthrough Therapy Designation in China for pevifoscorvir sodium.
Vertex to Acquire Crinetics for $10 Billion in Major Rare Disease Expansion
The deal adds PALSONIFY (paltusotine) and late-stage CAH therapy to Vertex’s portfolio.
CMS Reverses Course on Medicare Reimbursement for Orthofix Bone Growth Stimulators
Medicare reversed a pay cut for Orthofix devices, restoring revenue outlook and boosting the stock on improved earnings visibility.